Biomarkers for Gastric Cancer Screening and Early Diagnosis.
Cristina Herrera-Pariente, Sheyla Montori, Joan Llach...
https://pubmed.ncbi.nlm.nih.gov/34680565/Actively Recruiting
Led by EDUARDO ALBENIZ · Updated on 2026-10-21
1200
Participants Needed
15
Research Sites
117 weeks
Total Duration
Researchers are conducting a multicenter, prospective cohort study in Spain to better understand and improve early detection and prevention of gastric cancer GC, a common and deadly cancer. The study aims to identify individuals at high risk for GC using clinical, endoscopic, and molecular approaches by analyzing patient data, life habits, and biological samples collected from over 600 patients with GC, about 50 patients with premalignant gastric lesions and early gastric cancers treated by endoscopy, and no less than 600 healthy participants over more than 18 months. Participants are grouped into cohorts based on their condition symptomatic patients undergoing diagnostic gastroscopy to study premalignant gastric lesions EDGAR 1, patients with premalignant lesions or early GC treated by endoscopic resection EDGAR 2, patients diagnosed with GC EPIGASTRIC, and a control group without gastric pathology or family history of GC. The study uses high-definition endoscopy and multiomic techniques to characterize lesions and identify biomarkers, as well as genomic studies to find hereditary predispositions. During the study, participants will complete life habits surveys and provide clinical data and biological samples for analysis. Researchers will evaluate the prevalence and characteristics of premalignant lesions, risk factors from clinical and lifestyle data, and new biomarkers for early GC diagnosis. Data is collected securely online, and statistical analyses will assess associations between variables and GC risk. The study will continue up to 10 years to develop new early diagnosis strategies and preventive measures to reduce GC mortality and incidence.
CONDITIONS
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
L
Leticia Moreira, MD, PhD
E
Eduardo Albéniz, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
EDUARDO ALBENIZ
Lead Sponsor
Miguel Servet Foundation/Navarrabiomed, Spain
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants complete lifestyle surveys, provide clinical data and biological samples, and may undergo endoscopic evaluations as applicable. Researchers analyze samples and clinical information to identify risk factors and biomarkers.
Regular visits depending on cohort and assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Cristina Herrera-Pariente, Sheyla Montori, Joan Llach...
https://pubmed.ncbi.nlm.nih.gov/34680565/Cristina Herrera-Pariente, Roser Capó-García, Marcos Díaz-Gay...
https://pubmed.ncbi.nlm.nih.gov/33525650/EDUARDO ALBENIZ
Lead Sponsor
Miguel Servet Foundation/Navarrabiomed, Spain
Collaborating Sponsor